Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Several drugs targeting poly(ADP-ribose) polymerase (PARP) enzymes are under development. Responses have been observed in patients with germline mutations in BRCA1 and BRCA2, with further data supporting antitumour activity of PARP inhibitors in sporadic ovarian cancer. Strategies to identify other predictive biomarkers remain under investigation. Iniparib was purported to be a PARP inhibitor that showed promising results in randomized phase II trials in patients with triple-negative breast cancer. Negative results from a phase III study in this disease setting, however, tempered enthusiasm for this agent. Recently, data from in vitro experiments suggest that iniparib is not only structurally distinct from other described PARP inhibitors, but is also a poor inhibitor of PARP activity. In this context, the negative iniparib phase III data might have erroneously promulgated the notion that PARP inhibition is not an effective therapeutic strategy. Here, we scrutinize the development of iniparib from preclinical studies to registration trials, and identify and discuss the pitfalls in the development of anticancer drugs to prevent future late-stage trial failures.

[1]  T. Fojo,et al.  Why do phase III clinical trials in oncology fail so often? , 2012, Journal of the National Cancer Institute.

[2]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[4]  E. Kun,et al.  Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide. , 2009, Molecular medicine reports.

[5]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[6]  Daowen Wang,et al.  Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors , 2011, Molecular Cancer.

[7]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[9]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[10]  I. Thompson,et al.  Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Lillian L. Siu,et al.  Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.

[12]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[13]  A. Secord,et al.  Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. , 2012, Gynecologic oncology.

[14]  D. Bergstrom,et al.  Abstract A226: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. , 2011 .

[15]  R. Wenstrup,et al.  Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer , 2012, Cancer.

[16]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[17]  P. Bach Limits on Medicare's ability to control rising spending on cancer drugs. , 2009, The New England journal of medicine.

[18]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[19]  E. Alli,et al.  Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.

[20]  E. Kun,et al.  Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. , 1995, Biochemical pharmacology.

[21]  U. Matulonis,et al.  A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Telfer,et al.  Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft , 2011, Molecular Cancer Therapeutics.

[23]  Robert Almassy,et al.  Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.

[24]  I Judson,et al.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? , 2009, British Journal of Cancer.

[25]  K Miller,et al.  A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Shapiro,et al.  Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells , 2012, Breast Cancer Research and Treatment.

[27]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[28]  Roger Collier,et al.  Rapidly rising clinical trial costs worry researchers , 2009, Canadian Medical Association Journal.

[29]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[30]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[31]  Karol Sikora,et al.  Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.

[32]  John E. Harlan,et al.  Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor , 2011, Clinical Cancer Research.

[33]  Eric P Kaldjian,et al.  Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. , 2010, Genes & cancer.

[34]  P. Workman Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[35]  C. Aring,et al.  A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.

[36]  P. LoRusso,et al.  Translating Clinical Trials into Meaningful Outcomes , 2010, Clinical Cancer Research.

[37]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[38]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 , 2009, Clinical Cancer Research.

[39]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[40]  F. Couch,et al.  Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter* , 2008, Journal of Biological Chemistry.

[41]  S. Powell,et al.  BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II , 2007 .

[42]  S. Powell,et al.  BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. , 2005, Cancer research.

[43]  I. Roninson,et al.  Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer , 2009 .

[44]  Manash S. Chatterjee,et al.  The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.

[45]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[46]  L. Elmore,et al.  Telomerase as a Target for Cancer Immunotherapy , 2003, Cancer biology & therapy.

[47]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[48]  L. Hutchinson,et al.  High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.

[49]  J. Baselga,et al.  SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). , 2012 .

[50]  T. Fojo,et al.  Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. , 2012, Journal of the National Cancer Institute.

[51]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[52]  S. Mathoulin-Pélissier,et al.  How valid are claims for synergy in published clinical studies ? , 2022 .

[53]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[54]  P. Workman Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[55]  J. O’Shaughnessy,et al.  Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. , 2008, Clinical breast cancer.

[56]  S. Lipsitz,et al.  Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[58]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[60]  A. Tolcher,et al.  A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors , 2008 .

[61]  C. Glenn Begley,et al.  Raise standards for preclinical cancer research , 2012 .

[62]  T. Yap,et al.  Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. , 2010, European journal of cancer.

[63]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[64]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[65]  Scott H. Kaufmann,et al.  Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.

[66]  G. Giaccone,et al.  A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors , 2012, Clinical Cancer Research.

[67]  J. Hainsworth,et al.  A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. , 2008, Clinical breast cancer.

[68]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[69]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[70]  J. Arrowsmith Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[71]  E. Kun,et al.  Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. , 2002, Biochemical pharmacology.

[72]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  I. Roninson,et al.  Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(−) triple-negative breast cancer (TNBC) cell line , 2011 .

[75]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Arrowsmith Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[77]  Jennifer L Moseley,et al.  First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors , 2008 .

[78]  J. Manola,et al.  PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. , 2013 .

[79]  M. Telli Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.